Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that, when given chronically, alters different neurotransmitter systems. To assess functional changes occurring in the 5-HT and dopaminergic systems, we investigated the effects of 5-HT1A agonist 8-hydroxy-2(di-N- propylamino)tetralin (8-OH-DPAT), of the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2- aminopropane (DOI) and of the dopamine D1/2 agonist apomorphine (APO) on behavior and on regional cerebral metabolic rates for glucose (rCMRglc) in rats pretreated for 3 weeks with saline or fluoxetine (8 mg/kg/day). Behavioral effects were assessed for 8-OH-DPAT by scoring the 5-HT syndrome, for DOI by counting head shakes and for APO with an activity monitor. rCMRglc were measured with quantitative autoradiographic [14C]2-deoxyglucose technique in 60 brain regions at 10 min after acute administration of 8-OH-DPAT 1 mg/kg, at 30 min after DOI 5 mg/kg or at 10 min after APO 1 mg/kg. Chronic fluoxetine did not alter the 5-HT syndrome by 8-OH-DPAT, decreased head shakes by DOI and enhanced hyperlocomotion by APO. 8-OH- DPAT produced rCMRglc increases in sensorimotor regions that were unaffected by fluoxetine pretreatment and diffuse metabolic decrements that were attenuated by fluoxetine in limbic and raphe areas (17% and 4% mean decreases, respectively, in saline control and fluoxetine- pretreated rats). DOI produced widespread rCMRglc declines that were intensified by fluoxetine (14% and 20% decreases, in control and fluoxetine rats). APO caused rCMRglc increases in 22 brain regions that were potentiated by fluoxetine in dopaminergic motor areas (10% and 25% increases, in control and fluoxetine rats). In conclusion, fluoxetine enhances 5-HT neurotransmission by blunting responsivity of 5-HT1A autoreceptors and increasing that of 5-HT2A/2C postsynaptic receptors and enhances dopaminergic D1/2 receptor neurotransmission.

Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT(1A) agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT(2A/2C) agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist apomorphine

FREO, ULDERICO;ERMANI, MARIO;ORI, CARLO
2010

Abstract

Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that, when given chronically, alters different neurotransmitter systems. To assess functional changes occurring in the 5-HT and dopaminergic systems, we investigated the effects of 5-HT1A agonist 8-hydroxy-2(di-N- propylamino)tetralin (8-OH-DPAT), of the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2- aminopropane (DOI) and of the dopamine D1/2 agonist apomorphine (APO) on behavior and on regional cerebral metabolic rates for glucose (rCMRglc) in rats pretreated for 3 weeks with saline or fluoxetine (8 mg/kg/day). Behavioral effects were assessed for 8-OH-DPAT by scoring the 5-HT syndrome, for DOI by counting head shakes and for APO with an activity monitor. rCMRglc were measured with quantitative autoradiographic [14C]2-deoxyglucose technique in 60 brain regions at 10 min after acute administration of 8-OH-DPAT 1 mg/kg, at 30 min after DOI 5 mg/kg or at 10 min after APO 1 mg/kg. Chronic fluoxetine did not alter the 5-HT syndrome by 8-OH-DPAT, decreased head shakes by DOI and enhanced hyperlocomotion by APO. 8-OH- DPAT produced rCMRglc increases in sensorimotor regions that were unaffected by fluoxetine pretreatment and diffuse metabolic decrements that were attenuated by fluoxetine in limbic and raphe areas (17% and 4% mean decreases, respectively, in saline control and fluoxetine- pretreated rats). DOI produced widespread rCMRglc declines that were intensified by fluoxetine (14% and 20% decreases, in control and fluoxetine rats). APO caused rCMRglc increases in 22 brain regions that were potentiated by fluoxetine in dopaminergic motor areas (10% and 25% increases, in control and fluoxetine rats). In conclusion, fluoxetine enhances 5-HT neurotransmission by blunting responsivity of 5-HT1A autoreceptors and increasing that of 5-HT2A/2C postsynaptic receptors and enhances dopaminergic D1/2 receptor neurotransmission.
2010
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/2441318
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact